South Korea's L&C Bio, maker of the market-leading Re2O injection, says it has signed a distribution contract worth at least $60 million over five years to introduce the treatment to the US next year. The product is made from donated human skin sourced from American tissue banks, a supply chain that Business Insider traced from US donors to Seoul clinics, and its planned entry is likely to test whether the injections can be sold without approval from federal regulators.
company
L&C Bio
South Korean biotech company